Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.

Bleecker ER, Siler T, Owen R, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:431-8. doi: 10.2147/COPD.S21073. Epub 2011 Aug 18.

2.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
3.

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.

Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:215-28. doi: 10.2147/COPD.S51592. eCollection 2014.

4.

Safety of indacaterol in the treatment of patients with COPD.

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:477-92. doi: 10.2147/COPD.S23816. Epub 2011 Sep 22.

5.

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.

Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2013;8:501-8. doi: 10.2147/COPD.S49615. Epub 2013 Oct 17. Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:85. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.

6.

Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.

Kerwin EM, Williams J.

Ther Adv Respir Dis. 2013 Feb;7(1):25-37. doi: 10.1177/1753465812470018. Epub 2013 Jan 7. Review.

PMID:
23296242
7.

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B; INTEGRAL Study Investigators.

Pulm Pharmacol Ther. 2011 Feb;24(1):162-8. doi: 10.1016/j.pupt.2010.06.005. Epub 2010 Jul 7.

PMID:
20619353
8.

Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.

Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.

Lung. 2013 Apr;191(2):135-46. doi: 10.1007/s00408-012-9444-2. Epub 2013 Jan 10. Review.

PMID:
23306410
9.

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.

Respir Med. 2013 Feb;107(2):223-32. doi: 10.1016/j.rmed.2012.10.022. Epub 2012 Dec 6.

10.
11.

Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.

Pulm Pharmacol Ther. 2007;20(6):740-9. Epub 2006 Sep 30.

PMID:
17088091
12.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
13.

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.

Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 31;9:813-24. doi: 10.2147/COPD.S59673. eCollection 2014. Review.

14.

Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.

Siler TM, LaForce CF, Kianifard F, Williams J, Spangenthal S.

Int J Chron Obstruct Pulmon Dis. 2014 Sep 1;9:919-25. doi: 10.2147/COPD.S67356. eCollection 2014.

15.
16.

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators.

Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62. doi: 10.1164/rccm.200910-1500OC. Epub 2010 May 12.

PMID:
20463178
17.

New developments in the management of COPD: clinical utility of indacaterol 75 μg.

Steiropoulos P, Archontogeorgis K, Nena E, Bouros D.

Int J Chron Obstruct Pulmon Dis. 2014;9:1-7. doi: 10.2147/COPD.S24940. Epub 2013 Dec 6. Review.

18.

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.

Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR.

Respir Res. 2011 Apr 26;12:54. doi: 10.1186/1465-9921-12-54.

19.

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.

Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 14;11:3189-3197. doi: 10.2147/COPD.S116786. eCollection 2016.

20.

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.

Horita N, Kaneko T.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 21;10:813-22. doi: 10.2147/COPD.S56067. eCollection 2015. Review.

Supplemental Content

Support Center